Radioactive antibody targets tough prostate cancer in early trial

NCT ID NCT07259213

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tests a new drug called 161Tb-RAD402 in 73 men with castration-resistant prostate cancer, a type that has stopped responding to hormone therapy. The drug is a radioactive antibody designed to seek out and attack cancer cells by targeting a protein called free PSA. The main goals are to check safety, find the right dose, and see if it can shrink tumors or lower PSA levels.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CASTRATION-RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Icon Cancer Centre Hollywood

    RECRUITING

    Nedlands, Western Australia, 6009, Australia

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Wollongong Hospital

    RECRUITING

    Wollongong, New South Wales, 2500, Australia